{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T00:06:23Z","timestamp":1787097983517,"version":"build-2736575974"},"reference-count":20,"publisher":"Wiley","issue":"11","license":[{"start":{"date-parts":[[2012,3,27]],"date-time":"2012-03-27T00:00:00Z","timestamp":1332806400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["bjui-journals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["BJU International"],"published-print":{"date-parts":[[2012,12]]},"abstract":"<jats:sec>\n                    <jats:label\/>\n                    <jats:p>Study Type \u2013 Therapy (RCT)<\/jats:p>\n                    <jats:p>Level of Evidence\u20031b<\/jats:p>\n                    <jats:p>\n                      <jats:bold>What's known on the subject? and What does the study add?<\/jats:bold>\n                    <\/jats:p>\n                    <jats:p>Avanafil is a potent selective phosphodiesterase type 5 (PDE5) inhibitor newly developed for treating erectile dysfunction (ED). Preclinical and clinical phase I studies showed that avanafil had enhanced selectivity, faster onset of action and a favourable side\u2010effect profile relative to currently available PDE5 inhibitors.<\/jats:p>\n                    <jats:p>As the result of phase III clinical trial for the efficacy and safety of avanafil treatment (100 and 200\u2003mg), taken as needed over a period of 12 weeks, in Korean patients with ED, avanafil is an effective and well\u2010tolerated therapy for ED of broad\u2010spectrum aetiology and severity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>OBJECTIVE<\/jats:title>\n                    <jats:p>\n                      <jats:list list-type=\"explicit-label\">\n                        <jats:list-item>\n                          <jats:p>To evaluate the efficacy and safety of avanafil, a new potent selective phosphodiesterase type 5 (PDE5) inhibitor, in patients with erectile dysfunction (ED).<\/jats:p>\n                        <\/jats:list-item>\n                      <\/jats:list>\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>PATIENTS AND METHODS<\/jats:title>\n                    <jats:p>\n                      <jats:list list-type=\"explicit-label\">\n                        <jats:list-item>\n                          <jats:p>The present study was a multicentre, randomized, double\u2010blind, placebo\u2010controlled, fix\u2010dosed phase three clinical trial involving 200 patients with ED.<\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>The subjects were treated with placebo or avanafil (100 or 200\u2003mg) for 12 weeks and were asked to complete the International Index of Erectile Function (IIEF), the Sexual Encounter Profile (SEP) diary, and the Global Assessment Questionnaire (GAQ).<\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>The primary outcome variable was the change from baseline for IIEF erectile function domain (EFD) score.<\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>The secondary outcome variables were SEP Q2 and Q3, the shift to normal rate (EFD \u2265 26), and response to the GAQ.<\/jats:p>\n                        <\/jats:list-item>\n                      <\/jats:list>\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>\n                      <jats:list list-type=\"explicit-label\">\n                        <jats:list-item>\n                          <jats:p>Compared with placebo, patients who took 100 or 200\u2003mg of avanafil had significantly improved IIEF\u2010EFD score.<\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>There were similar results when comparing Q2 and Q3 in the SEP diary and the GAQ.<\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>Flushing was the most common treatment\u2010related adverse event.<\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>Most adverse events were transient and mild or moderate in severity.<\/jats:p>\n                        <\/jats:list-item>\n                      <\/jats:list>\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSION<\/jats:title>\n                    <jats:p>\n                      <jats:list list-type=\"explicit-label\">\n                        <jats:list-item>\n                          <jats:p>Avanafil is an effective and well\u2010tolerated therapy for ED of broad\u2010spectrum aetiology and severity.<\/jats:p>\n                        <\/jats:list-item>\n                      <\/jats:list>\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/j.1464-410x.2012.11095.x","type":"journal-article","created":{"date-parts":[[2012,3,27]],"date-time":"2012-03-27T08:24:14Z","timestamp":1332836654000},"page":"1801-1806","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":42,"title":["Efficacy and safety of avanafil for treating erectile dysfunction: results of a multicentre, randomized, double\u2010blind, placebo\u2010controlled trial"],"prefix":"10.1111","volume":"110","author":[{"given":"Chen","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sae Woong","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dae Yul","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Je Jong","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nam Cheol","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung Won","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jae Seung","family":"Paick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tai Young","family":"Ahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ki Hak","family":"Moon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Woo Sik","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kweon Sik","family":"Min","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun\u2010Kyu","family":"Suh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jae Seog","family":"Hyun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kwangsung","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jong Kwan","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2012,3,27]]},"reference":[{"key":"e_1_2_7_2_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199805143382001"},{"key":"e_1_2_7_3_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.ijir.3900567"},{"key":"e_1_2_7_4_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.ju.0000164463.19239.19"},{"key":"e_1_2_7_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2006.01.028"},{"key":"e_1_2_7_6_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2005.05614.x"},{"key":"e_1_2_7_7_2","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1111\/j.1742-1241.2002.tb11296.x","article-title":"Pharmacology of phosphodiesterase\u20105 inhibitor","volume":"56","author":"Corbin JD","year":"2002","journal-title":"Int J Clin Pract"},{"key":"e_1_2_7_8_2","first-page":"243","article-title":"After two years, did Viagra live up to its expectations?","volume":"98","author":"Madduri SD","year":"2001","journal-title":"Mo Med"},{"key":"e_1_2_7_9_2","doi-asserted-by":"publisher","DOI":"10.1517\/13543784.2010.518955"},{"key":"e_1_2_7_10_2","doi-asserted-by":"publisher","DOI":"10.2174\/156802607779941288"},{"key":"e_1_2_7_11_2","doi-asserted-by":"publisher","DOI":"10.1152\/physrev.1995.75.4.725"},{"key":"e_1_2_7_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2010.06.011"},{"key":"e_1_2_7_13_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1993.03510010089036"},{"key":"e_1_2_7_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(05)64442-4"},{"key":"e_1_2_7_15_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1743-6109.2007.00468.x"},{"key":"e_1_2_7_16_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.ijir.3900631"},{"key":"e_1_2_7_17_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1743-6109.2007.00723.x"},{"key":"e_1_2_7_18_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.ju.0000063377.12281.57"},{"key":"e_1_2_7_19_2","first-page":"820","article-title":"Erectile dysfunction. New drugs with special consideration of the PDE 5 inhibitors","volume":"43","author":"Porst H","year":"2004","journal-title":"Urologe A"},{"key":"e_1_2_7_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0090-4295(02)01752-1"},{"key":"e_1_2_7_21_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200565120-00003"}],"container-title":["BJU International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1464-410X.2012.11095.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bjui-journals.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1464-410X.2012.11095.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T17:20:46Z","timestamp":1761758446000},"score":1,"resource":{"primary":{"URL":"https:\/\/bjui-journals.onlinelibrary.wiley.com\/doi\/10.1111\/j.1464-410X.2012.11095.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,3,27]]},"references-count":20,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2012,12]]}},"alternative-id":["10.1111\/j.1464-410X.2012.11095.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1464-410x.2012.11095.x","archive":["Portico"],"relation":{},"ISSN":["1464-4096","1464-410X"],"issn-type":[{"value":"1464-4096","type":"print"},{"value":"1464-410X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,3,27]]},"assertion":[{"value":"2012-03-27","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}